Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Tetanus01:29

Tetanus

Tetanus is a life-threatening neurological disorder characterized by persistent muscle contractions and spastic paralysis. It is caused by Clostridium tetani, a motile, Gram-positive, rod-shaped, obligate anaerobe. These bacteria produce terminal endospores, giving them a distinctive “lollipop” or “tennis-racket” appearance. They thrive in anaerobic environments, such as those found in deep puncture wounds.Once introduced into the body, the spores germinate into vegetative cells. These cells...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ataxia Global Initiative recommend MRI end-points for clinical trials in ataxias.

Nature reviews. Neurology·2026
Same author

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same authorSame journal

Ozzy Osbourne and Parkinson's disease: from darkness to awareness.

Arquivos de neuro-psiquiatria·2026
Same author

"Expert Commentary on Segmental brainstem myoclonus in ADCK3-related ataxia".

Parkinsonism & related disorders·2026
Same author

Cerebral palsy in art and literature throughout history.

Arquivos de neuro-psiquiatria·2026
Same author

Deep brain stimulation for dystonia: outcomes from a Brazilian cohort.

Arquivos de neuro-psiquiatria·2026

Related Experiment Video

Updated: May 28, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Neuroleptic malignant syndrome.

Mariana Moscovich1, Felipe T M Nóvak, Artur F Fernandes

  • 1Department of Neurology, Pontifical Catholic University of Paraná, Curitiba, PR, Brazil.

Arquivos De Neuro-Psiquiatria
|November 2, 2011
PubMed
Summary

Neuroleptic malignant syndrome (NMS), a severe reaction to antipsychotics (AP), was studied in 18 patients. Most cases involved women on high-dose AP, with symptoms similar to previous reports and a high recovery rate.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Related Experiment Videos

Last Updated: May 28, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Area of Science:

  • Pharmacology
  • Clinical Neurology
  • Psychiatry

Background:

  • Neuroleptic malignant syndrome (NMS) is a rare but life-threatening adverse drug reaction.
  • Antipsychotic (AP) medications are frequently used for psychiatric disorders, increasing the risk of NMS.
  • Understanding NMS patient profiles is crucial for early diagnosis and management.

Purpose of the Study:

  • To investigate the demographic and clinical characteristics of NMS cases.
  • To compare NMS patient profiles with findings from similar studies.
  • To assess the role of different types of antipsychotics in NMS development.

Main Methods:

  • Retrospective analysis of 18 consecutive NMS cases.
  • Data collection included patient demographics, psychiatric history, and AP treatment details.
  • Clinical signs and symptoms of NMS episodes were systematically recorded.

Main Results:

  • Two-thirds of NMS cases occurred in women with prior psychiatric conditions, often on high-dose AP.
  • Observed NMS signs and symptoms aligned with previously published data.
  • While 68% of patients used typical (classic) AP, newer agents also presented NMS risk.
  • Only one fatal outcome was recorded; the rest achieved full recovery.

Conclusions:

  • NMS patient profiles are consistent with existing literature, emphasizing risk factors like female sex and high-dose AP.
  • Both typical and newer antipsychotics can precipitate NMS.
  • Prompt recognition and management of NMS are associated with favorable outcomes.